These data provide further evidence of B-cell involvement in the pathogenesis of scleroderma and targeting B cells may be a promising treatment for scleroderma patients. PubMed, Clin Exp Rheumatol, 2015 Sep-Oct;33 Suppl 91(4):160-167. (Also see B Cells and T Cells and Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.